Phototherapy and Biologics for Psoriasis

Phototherapy and Biologics for Psoriasis

Phototherapy and Biologics for Psoriasis

On this page

Phototherapy - Sunbeams & Skin

  • Mechanism: Immunomodulatory (↓T-cell activity), antiproliferative (↓keratinocyte turnover).
  • Types:
    • NB-UVB (Narrowband UVB): 311-313 nm. First-line. Good efficacy, safer profile (children, pregnancy).
    • PUVA (Psoralen + UVA): Psoralen (oral/topical) + UVA (320-400 nm). Highly effective for severe cases. Higher risk.
  • Indications: Moderate-severe widespread plaque, guttate, or palmoplantar psoriasis.
  • Adverse Effects (AEs):
    • NB-UVB AEs: Erythema, pruritus, xerosis, long-term photoaging.
    • PUVA AEs: Nausea, phototoxicity, ↑ Squamous Cell Carcinoma (SCC) risk, cataracts. 📌 PUVA: Psoralens Used, Very Aware of SCC. NB-UVB phototherapy unit for psoriasis treatment

⭐ NB-UVB is preferred for maintenance therapy due to its lower cumulative toxicity and reduced long-term skin cancer risk.

Biologics Intro & Screening - Psoriasis Precision Strikes

  • What: Engineered proteins targeting specific immune mediators (cytokines, receptors). "Precision strikes."
  • Indications: Moderate-severe plaque psoriasis, psoriatic arthritis; unresponsive/contraindicated to conventional systemic therapies.
  • Broad Classes: TNF-α, IL-17, IL-23, IL-12/23 inhibitors.
  • Pre-treatment Screening (Mandatory):
    • Tuberculosis: IGRA (preferred) or TST; Chest X-ray. Treat latent TB.
    • Viral Hepatitis: HBsAg, Anti-HCV, HIV.
    • Labs: CBC, LFTs, KFTs, lipid profile.
    • Exclude: Active serious infection, demyelinating disorders, mod-severe CHF (NYHA Class III/IV), current/recent malignancy. Psoriasis Biologics Pre-treatment Screening Protocol

⭐ All patients MUST be screened for latent TB (IGRA or TST & CXR) before initiating biologic therapy due to significant reactivation risk.

TNF-α Inhibitors - Tumour Necrosis Takedown

  • Mechanism: Bind TNF-α, block receptor interaction.
  • Key Drugs:
    • Etanercept (fusion protein).
    • Infliximab (chimeric mAb).
    • Adalimumab (human mAb).
  • ⚠️ Adverse Effects:
    • ↑ Infection risk (TB reactivation; screen prior).
    • Demyelinating disorders.
    • Drug-induced lupus.
    • Worsening heart failure.
    • Malignancy.
  • 📌 Mnemonic: "ETA IN ADA" (Etanercept, Infliximab, Adalimumab). TNF alpha inhibitors therapeutic cheat sheet

⭐ Screening for latent TB (Mantoux/IGRA) is mandatory before starting TNF-α inhibitors due to reactivation risk.

Interleukin Inhibitors - Cytokine Cascade Control

  • Target key cytokines: IL-12, IL-23, IL-17.
  • IL-12/23 Inhibitor (p40 subunit):
    • Ustekinumab: Psoriasis, psoriatic arthritis. 45/90mg SC 0, 4 wks, then q12w.
  • IL-17 Inhibitors (IL-17A/IL-17RA): Rapid onset.
    • Secukinumab (IL-17A): 300mg SC (load, then monthly).
    • Ixekizumab (IL-17A): 80mg SC (load, then q2-4w).
    • Brodalumab (IL-17RA): ⚠️ Suicidal ideation risk.

      ⭐ Brodalumab (IL-17RA blocker) has a black box warning for suicidal ideation/behavior.

  • IL-23 Inhibitors (p19 subunit): Selective.
    • Guselkumab: 100mg SC q8w (post-load).
    • Risankizumab: 150mg SC q12w (post-load).
    • Tildrakizumab: 100mg SC q12w (post-load).
  • TB screening essential pre-treatment. IL-17A pathway in systemic inflammation and psoriasis

Biologic Management - Navigating Advanced Care

  • Pre-treatment: Screen for latent TB (QuantiferON-TB Gold/Mantoux), HBV, HCV.
  • Monitoring: Watch for infections. Regular CBC, LFTs. Evaluate response (e.g., PASI 75).
  • Choice Factors: Severity (PASI), type (PsA), comorbidities (IBD, demyelination, CHF), patient preference, prior therapy.
  • Vaccinations: Inactivated vaccines 2-4 weeks prior. Live vaccines strictly contraindicated during therapy.

⭐ All patients must be screened for latent tuberculosis before initiating biologic therapy due to risk of reactivation.

High-Yield Points - ⚡ Biggest Takeaways

  • NB-UVB (311 nm) is preferred phototherapy; safer than PUVA.
  • PUVA (Psoralen + UVA) increases SCC risk; requires eye protection.
  • Biologics target: TNF-α (infliximab), IL-12/23 (ustekinumab), IL-17 (secukinumab), IL-23p19 (guselkumab).
  • Screen for latent TB, Hepatitis B/C, HIV before starting biologics.
  • TNF-α inhibitors: Risk of TB reactivation, demyelination, worsening heart failure.
  • IL-17 inhibitors: Risk of candidiasis, may worsen IBD.
  • Ustekinumab targets p40 subunit of IL-12/IL-23.

Practice Questions: Phototherapy and Biologics for Psoriasis

Test your understanding with these related questions

What is the primary condition for which calcitriol is used as a treatment?

1 of 5

Flashcards: Phototherapy and Biologics for Psoriasis

1/10

Tildrakizumab is a monoclonal antibody indicated in moderate-to-severe _____

TAP TO REVEAL ANSWER

Tildrakizumab is a monoclonal antibody indicated in moderate-to-severe _____

plaque psoriasis

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial